TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ACRV

Acrivon Therapeutics, Inc.

Healthcare · Biotechnology

1.70$ +0.0% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Acrivon Therapeutics, Inc. (ACRV)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 59.9% of the shares are freely tradable; institutional investors hold 47.4%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 47.4%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 15.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 59.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 43Mio.

Largest Shareholders

Institutions

Institutions ACRV
Name Stake (%) Shares Change (%) Date
RA Capital Management, LLC 19.46 8,340,508 +0.0 03/31/2026
Sands Capital Ventures, LLC 5.34 2,289,271 +7.9 06/30/2026
Wellington Management Company LLP 2.07 888,130 +0.0 06/30/2026
Acadian Asset Management LLC 1.97 845,973 +175,778.0 03/31/2026
Renaissance Technologies Corp 1.77 758,440 +19.6 03/31/2026
Vanguard Capital Management, LLC 1.68 722,035 +0.0 03/31/2026
Two Sigma Investments LLC 1.50 641,498 +64.7 06/30/2026
Marshall Wace Asset Management Ltd 1.31 560,436 +13.0 03/31/2026

Funds

Funds ACRV
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.27 545,541 +0.0 07/31/2026
Vanguard Institutional Extnd Mkt Idx Tr 0.91 389,575 +0.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings ACRV
Person Role Shares Value As of Type
Blume-Jensen Peter President and CEO 2,615,911 4,447,049 $ Aug 18, 2026 both
Devroe Eric Chief Operating Officer 146,349 248,793 $ Aug 18, 2026 direct
Miller Mary Chief Legal Officer 82,009 139,415 $ Aug 18, 2026 direct
Levy Adam D. Chief Financial Officer 66,008 112,214 $ Aug 4, 2026 direct
Gamelin Erick Chief Development Officer 52,592 89,406 $ Aug 18, 2026 direct
Levin Michaela Chief Business Officer 30,000 51,000 $ Aug 31, 2026 direct
Peterson Katharine Chief Accounting Officer 18,033 30,656 $ Aug 18, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Aug 31, 2026 Levin Michaela Chief Business Officer Other 30,000 0.00
Aug 25, 2026 Blume-Jensen Peter President and CEO Sell 14,036 2.21 30,969
Aug 18, 2026 Peterson Katharine Chief Accounting Officer Sell 101 2.01 203
Aug 18, 2026 Miller Mary Chief Legal Officer Sell 185 2.01 372
Aug 18, 2026 Gamelin Erick Chief Development Officer Sell 400 2.01 804
Aug 18, 2026 Devroe Eric Chief Operating Officer Sell 604 2.01 1,214
Aug 18, 2026 Blume-Jensen Peter President and CEO Sell 484 2.01 973
Aug 18, 2026 Blume-Jensen Peter President and CEO Sell 1,229 2.01 2,470
Aug 4, 2026 Levy Adam D. Chief Financial Officer Sell 1,142 1.57 1,793
Jul 21, 2026 Miller Mary Chief Legal Officer Sell 573 1.76 1,008

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?